Tianyin Pharmaceutical Co., Inc. (TPI)), a pharmaceutical company that specializes in patented biopharmaceutical medicine, modernized traditional Chinese medicine, branded generics and other pharmaceuticals has received China’s SFDA’s approval for its anti-diabetic drug Gliclazide Tablets.
Diabetes is one of the most common endocrine disorders in the world. The World Health Organization (WHO) estimates that worldwide, there are currently 220 million people living with diabetes. Diabetes is becoming an important chronic disease in China. In 2010, there were 95 million cases of diabetes in China, of which, 52 million and 43 million were found in rural and urban areas, respectively. By the end of 2020, it is estimated that the prevalence will increase to 117 million. The urbanization rates, obesity and population aging are several major drivers for the increasing type 2 diabetes incidence in China.
Gliclazide is an oral anti-diabetic drug that is used for the control of hyperglycemia. It is used when diabetes cannot be managed by proper dietary adjustment and exercise or when not suitable for insulin therapy. TPI is anticipating that its Gliclazide Tablets will make its market entry in July this year.
Headquartered at Chengdu, China, TPI currently manufactures a comprehensive portfolio of 56 products, 23 of which are listed in the highly selective national medicine reimbursement list, 7 are included in the essential drug list of China. TPI’s pipeline targets various high incidence healthcare indications. TPI, a presenting company at OneMedForum SF 2011, has an extensive nationwide distribution network with a sales force of 730 sales representatives out of totaled 1,365 employees.